Filing Flows

Filing Flows › Companies › Oncotelic Therapeutics › Cash flow

Oncotelic Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$92K in Q2 2026 · −$1.5M over twelve months

Operating cash flow−$92K
Free cash flow−$92K
Cash / net income-0.3×

Analysis

In Q2 2026, Oncotelic Therapeutics generated −$92K of operating cash flow. That is $34K more than in Q2 2025 (−$126K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$1.5M; the largest uses were operating cash flow ($1.5M); besides operations, cash came from other financing ($952K), net borrowing (+) / repaid (−) ($671K); the cash balance rose by $98K.

Operating cash flow was −$92K against net income of $341K — -0.3× profit, less cash than reported earnings, worth checking against working capital. The largest differences: stock-based pay +$730K, payables +$402K, prepaid and other assets −$220K.

Free cash flow

Oncotelic Therapeutics: free cash flow by quarterOncotelic Therapeutics: free cash flow by quarter−$143KQ3 2024−$104KQ4 2024−$167KQ1 2025−$126KQ2 2025−$307KQ3 2025−$783KQ4 2025−$342KQ1 2026−$92KQ2 2026
Operating cash flow less capital spending.
Oncotelic Therapeutics: operating cash flow against capital spendingOncotelic Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$143K$0Q3 2024−$104K$0Q4 2024−$167K$0Q1 2025−$126K$0Q2 2025−$307K$0Q3 2025−$783K$0Q4 2025−$342K$0Q1 2026−$92K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$92K, Capital spending $0.

Capital allocation, year by year

Oncotelic Therapeutics: where the cash came from (up) and went (down), by fiscal yearOncotelic Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedFY2021: Operating cash flow −$4.4MFY2021: Net borrowing $463KFY2021: Shares issued $420K$883KFY2021FY2022: Operating cash flow −$1.5MFY2022: Net borrowing $966KFY2022: Shares issued $159K$1.1MFY2022FY2023: Operating cash flow −$1.3MFY2023: Net borrowing $1.4M$1.4MFY2023FY2024: Operating cash flow −$740KFY2024: Net borrowing $656K$656KFY2024FY2025: Operating cash flow −$1.4MFY2025: Net borrowing $1.4M$1.4MFY2025
Over these 5 years operating cash flow totalled −$9.3M; the largest uses were operating cash flow ($9.3M). Cash-flow statements as filed.

Where the cash came from and went

Oncotelic Therapeutics: sources (+) and uses (−) of cash, Q2 2026Oncotelic Therapeutics: sources (+) and uses (−) of cash, Q2 2026Net borrowing (+) / repaid (−)$191KCash drawn (+) / kept (−)−$122KOperating cash flow−$92KOther financing$17KShares issued$7K
Oncotelic Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Oncotelic Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$1.5MOther financing$952KNet borrowing (+) / repaid (−)$671KCash drawn (+) / kept (−)−$98K

From profit to cash

Oncotelic Therapeutics: net income to operating cash flow, Q2 2026Oncotelic Therapeutics: net income to operating cash flow, Q2 2026Net income$341KStock-based pay$730KPayables$402KPrepaid and other assets−$220KOperating cash flow−$92K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$92K$191K$7K−$122K−$92K
Q1 2026−$342K$317K—$25K−$342K
Q4 2025−$783K$463K—$320K−$783K
Q3 2025−$307K$150K—−$321K−$307K
Q2 2025−$126K$135K—−$9K−$126K
Q1 2025−$167K$160K—$7K−$167K
Q4 2024−$104K$41K—$63K−$104K
Q3 2024−$143K$220K—−$77K−$143K

Oncotelic Therapeutics: income statement and cash flow

Oncotelic Therapeutics, Q2 2026: revenue $250K, operating margin -337.4%. The chart follows the revenue to costs, profit and cash.

Oncotelic Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.